Outcomes from the use of maximal androgen blockade in prostate cancer at health area with reference hospital type 2 (1st part). Quality of life: application of EORTC QLQ-C30 instrument.
OBJECTIVE
To analize the influence that maximal androgen blockade (MAB) exerts on quality of life in patients from the health area of Zamora diagnosed of prostate adenocarcinoma between 2000-2005.


METHODS
Basal, 12-month, 24-month and 36-month application of the health-related quality of life measurement instrument EORTC QLQ-PR25 to the population sample (n= 111), as well as a control sample (n= 100). We performed a comparative study of the outcomes between groups; between various time measurements in MAB patients; and inter-categories/ intervals of some variables in patients with hormonal deprivation therapy (third year of follow-up).


RESULTS
Cognitive and symptomatic fields were affected in patients with MAB at some specific time points. No field showed a significant constant worsening through the period of study for hormonally deprivated patients. A recovery is seen in the sociofamiliar field. Less academic level in MAB patients represents a distinguishing factor leading to worse outcomes in the health-related quality of life parameters analyzed here.


CONCLUSIONS
There is a negative initial repercussion of MAB on quality of life, although tinged according to the different fields studied.
Cruz Guerra
Nicolás Alberto
NA
Department of Urology, Complejo Asistencial de Zamora, Zamora, España. ncruz_g@hotmail.com
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D011795:Surveys and Questionnaires
D000726:Androgen Antagonists